Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

N/ACompletedNCT00683332

Pfizer621 enrolled

Overview

The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

Three-thousand or 10% of total number of patients given tigecycline will be included in the study

Study Type

OBSERVATIONAL

Enrollment

621

Conditions

Complicated Skin and Skin Structure Infections Complicated Intra-abdominal Infections

Interventions

Tigecycline (Tygacil)DRUG

This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * All patients from the study center who received or will receive at least one dose of Tygacil according to the approved product indication. Exclusion Criteria: * Previously discontinued Tygacil therapy due to significant safety concern.

Locations (1)

Pfizer Investigational Site

Manila, Philippines

Outcomes

Primary Outcomes

Number of Participants With Spontaneous Adverse Events

Adverse events were based on the signs or symptoms detected during the physical examination and on clinical evaluation of the participant. In addition to the information obtained from these sources, the participant was asked the following nonspecific question: "How have you been feeling since your last visit?"

Time frame: 30 days post injection up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.